Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst ...

Medical device company Globus Medical (NYSE:GMED) fell short of the market’s revenue expectations in Q1 CY2025, with sales ...

Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral. Analyst Price Forecast Suggests 68.61% Upside As of May 7, 2025, the average ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high estimate of $82.00, and a low estimate of $68.00. A negative shift in sentiment is ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Globus Medical, Inc. (NYSE:GMED – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat reports.